Physician profile
Robert April
NPI 1760598833
$5,986.74
in general payments reported to CMS, 2019-2025
44 companies · $676 in 2025
The $676 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $573 · 2021: $1,318 · 2022: $1,332 · 2023: $642 · 2024: $763 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,411.97 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Amgen INC. | $581.03 | 2019-2024 | Repatha |
| Qol Medical, LLC | $442.26 | 2021-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $384.98 | 2023-2025 | Kisunla, Emgality |
| Biogen, INC. | $347.64 | 2021-2022 | |
| Pfizer INC. | $327.75 | 2023-2025 | |
| Novo Nordisk INC | $315.91 | 2019-2025 | Wegovy |
| Allergan, INC. | $264.42 | 2019-2020 | |
| Amarin Pharma, INC. | $232.22 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $135.00 | 2022 | |
| Vertical Pharmaceuticals, LLC | $130.42 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $116.48 | 2022 | |
| Esperion Therapeutics, INC. | $108.81 | 2022-2025 | Nexletol |
| Glaxosmithkline, LLC. | $108.56 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Corium, LLC | $94.92 | 2022-2023 | Adlarity |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert April listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.